logo

EVIDENCE • EXPERIENCE • OUTCOMES

INTELLIGENCE BYMDReviewer
Home
About
Peptides
Contact
Back
  • No Preview Available

RELIANCE 4-FRONT

Device
Generic:
Implantable cardioverter defibrillator (non-CRT)
Manufacturer:
boston scientific
Drug Classes:
Not available
Reps:
Rep 1Signup or Login to view Reps
Rep 2Signup or Login to view Reps

👋No reviews yet — be the first!

Be the first verified prescriber to review RELIANCE 4-FRONT.

100% anonymous · NPI-verified

On this page

  • Synopsis

FDA label

  • Indication and Usage

More

  • Approval history
  • Representatives
  • Reviews

Similar products

Synopsis
Generated with AlphaAI
Product:
RELIANCE 4-FRONT
Category:
Indication:
Mechanism:
Safety:
Dosing:
Patient:
Reviews:
No reviews yet
see more
Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

FDA label

From the official FDA prescribing information for RELIANCE 4-FRONT.

Indication and Usage

The ENDOTAK® Lead System is a transvenous defibrillation leads system and is intended for the treatment of ventricular tacharrhythmias in patients who are at high risk of sudden cardiac death. Such patients are defined as those who have experienced one or more of the following: (1) survived at least one episode of cardiac arrest presumable due to hemodynamically unstable ventricular tachyarrhythmias unassociated with acute myocardial infarction; or (2) recurrent ventricular tachyarrhythmia’s in the absence of such previous arrest and are inducible into sustained hypotensive ventricular tachycardia (VT) or ventricular fibrillation (VF) despite conventional antiarrhythmic drug therapy.A major consideration in choosing the ENDOTAK® Lead System is that it does not require a thoracotomy. The physician should weigh its advantages against the patient’s ability to withstand additional electrophysiological (EP) testing (arrhythmia induction and conversion testing), and a possible thoracotomy, should the lead system prove ineffective.Various factors such as cardiomegaly or drug therapy may necessitate repositioning of the defibrillating leads, or substitution of one lead system for another in order to facilitate arrhythmia conversion. In some cases, reliable arrhythmia conversion may not be obtained with any leads at the available AICD™ energy levels.Bipolar pacmakers may be used with the ENDOTAK® Lead System and AICD™ pulse generator as long as the pacemaker and AICD™ pulse generator do not interact causing AICD™ pulse generator nondetection or false detection.The ENDOTAK® SQ Patch Lead is intended for chronic subcutaneous or submuscular implantation in conjunction with an ENDOTAK® C Lead. The ENDOTAK® SQ Patch Leas is not intended for epicardial or pericardial placement.

Approval history

Latest FDA approval: January 16, 2023

Representatives

J
John Doe
New York, US
Products:

Humira

Humira

J
John Doe
New York, US
Products:

Humira

Humira

Signup or Login to view Reps
You must have an account to view Reps detail
Already have an account? Login
There isn't any reviews posted yet. You can be the first to review the product